ARTICLE | Company News
FDA delays decision on Impax PD compound
October 13, 2012 1:14 AM UTC
FDA extended the PDUFA date by three months for an NDA from Impax Laboratories Inc. (NASDAQ:IPXL) for Rytary extended-release carbidopa/levodopa ( IPX066) to treat idiopathic Parkinson's disease (PD)....